Good Life Advisors LLC Boosts Stock Holdings in Stryker Co. (NYSE:SYK)

Good Life Advisors LLC lifted its stake in Stryker Co. (NYSE:SYK) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,764 shares of the medical technology company’s stock after buying an additional 146 shares during the period. Good Life Advisors LLC’s holdings in Stryker were worth $1,355,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of SYK. Whittier Trust Co. increased its position in shares of Stryker by 24.0% in the third quarter. Whittier Trust Co. now owns 4,150 shares of the medical technology company’s stock valued at $1,499,000 after acquiring an additional 804 shares during the period. Foundations Investment Advisors LLC grew its stake in shares of Stryker by 10.0% in the third quarter. Foundations Investment Advisors LLC now owns 1,753 shares of the medical technology company’s stock worth $633,000 after purchasing an additional 160 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in Stryker by 1.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 11,236 shares of the medical technology company’s stock valued at $4,059,000 after purchasing an additional 187 shares during the period. Eastern Bank raised its position in Stryker by 313.5% during the 3rd quarter. Eastern Bank now owns 3,730 shares of the medical technology company’s stock valued at $1,347,000 after purchasing an additional 2,828 shares during the last quarter. Finally, Stanley Laman Group Ltd. lifted its holdings in Stryker by 83.4% in the 3rd quarter. Stanley Laman Group Ltd. now owns 1,379 shares of the medical technology company’s stock worth $498,000 after buying an additional 627 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.7 %

NYSE:SYK opened at $388.30 on Thursday. The stock has a market cap of $148.17 billion, a price-to-earnings ratio of 50.04, a PEG ratio of 2.90 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company’s 50 day moving average price is $377.69 and its 200-day moving average price is $368.08. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the business posted $3.46 EPS. On average, equities research analysts forecast that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Analysts Set New Price Targets

SYK has been the subject of a number of recent analyst reports. Piper Sandler restated an “overweight” rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Robert W. Baird upped their price objective on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Barclays lifted their target price on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Stifel Nicolaus lifted their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

Insider Transactions at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.